Apple and Eli Lilly are both showing promise with potential for growth and dividends. Apple has rebounded despite challenges, like tariffs and AI developments, with new product releases sparking interest. Eli Lilly faces some setbacks but also has upcoming approvals and promising pipeline candidates. Both companies have seen stock price increases and are considered top picks for investors. Apple’s recent financial results show strength in active devices and services segments. Eli Lilly’s recent performance and pipeline progress indicate strong sales and earnings growth. Both companies have increased dividends over the past decade, making them attractive options for investors. The Motley Fool’s Stock Advisor team has identified 10 stocks to buy now, excluding Apple, which they believe could offer significant returns in the future. Investing in top-performing stocks identified by Stock Advisor has historically led to impressive returns compared to the S&P 500. Consider joining Stock Advisor to access their latest top 10 list and potentially capitalize on future market opportunities. Prosper Junior Bakiny holds positions in Eli Lilly and Novo Nordisk, while The Motley Fool has positions in and recommends Apple and also recommends Novo Nordisk.

Read more at NASDAQ: These 2 Top Dividend Stocks Are Finally Rebounding, and There Might Be More Upside Ahead